Idorsia's Daridorexant Shows Positive Phase 2 Results In Paediatric Insomnia; Stock Up

Idorsia announced positive top-line Phase 2 dose-finding results for daridorexant at 10, 25 and 50 mg; detailed efficacy and safety metrics were not provided in the release. The outcome supports progression of the investigational dual orexin receptor antagonist into later-stage development and could lift Idorsia's pipeline valuation and near-term stock performance if full data confirm the topline.

Analysis

Idorsia announced positive top-line Phase 2 dose-finding results for daridorexant at 10, 25 and 50 mg; detailed efficacy and safety metrics were not provided in the release. The outcome supports progression of the investigational dual orexin receptor antagonist into later-stage development and could lift Idorsia's pipeline valuation and near-term stock performance if full data confirm the topline.